Multiple myeloma is a type of cancer that affects plasma cells, a type of white blood cell found in the bone marrow.
Get the full solved assignment PDF of MME-106/As-2 of 2024 session now.
It primarily affects older adults, with the median age at diagnosis being around 69 years old. Here’s an overview of multiple myeloma in elderly patients:
**1. Presentation:**
- Multiple myeloma can present with a variety of symptoms, including bone pain (especially in the back, ribs, and hips), weakness, fatigue, recurrent infections, anemia, kidney dysfunction, hypercalcemia, and neurological symptoms (e.g., numbness, weakness, tingling).
**2. Diagnosis:**
– Diagnosis of multiple myeloma involves a combination of clinical evaluation, laboratory tests, imaging studies, and bone marrow biopsy.
– Laboratory tests typically show abnormalities such as monoclonal gammopathy (elevated levels of monoclonal proteins or M-proteins), elevated serum or urine protein levels, and abnormalities in blood counts (e.g., anemia, thrombocytopenia, leukopenia).
– Imaging studies such as X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans may be used to evaluate bone lesions and assess the extent of disease involvement.
– Bone marrow biopsy and aspiration are performed to examine the bone marrow for abnormal plasma cells and assess the percentage of plasma cells present (plasma cell infiltration).
**3. Treatment:**
– Treatment of multiple myeloma in elderly patients is tailored based on factors such as age, overall health, disease characteristics, and treatment goals.
– The mainstays of treatment include chemotherapy, immunomodulatory drugs (e.g., lenalidomide, pomalidomide), proteasome inhibitors (e.g., bortezomib, carfilzomib), corticosteroids (e.g., dexamethasone), and monoclonal antibodies (e.g., daratumumab, elotuzumab).
– Autologous stem cell transplantation (ASCT) may be considered for eligible patients who are fit enough to undergo the procedure and have adequate organ function.
– Supportive care measures, including bisphosphonates to reduce the risk of skeletal-related events (e.g., fractures, spinal cord compression), management of anemia and other complications, and supportive therapies (e.g., pain management, antibiotics for infections), are important components of treatment.
**4. Prognosis:**
– The prognosis of multiple myeloma in elderly patients varies depending on factors such as age, overall health, stage of disease, response to treatment, and presence of adverse cytogenetic abnormalities.
– With advancements in treatment options, including novel targeted therapies and immunotherapies, survival outcomes for elderly patients with multiple myeloma have improved in recent years.
– However, multiple myeloma remains an incurable disease, and the goal of treatment is typically to control the disease, prolong survival, and improve quality of life.
**5. Supportive Care:**
– Supportive care plays a critical role in the management of elderly patients with multiple myeloma, focusing on symptom management, pain control, maintenance of nutritional status, management of comorbidities, and psychosocial support.
– Palliative care and hospice services may be incorporated into the care plan to address end-of-life care needs and provide holistic support for patients and their families.
Overall, the management of multiple myeloma in elderly patients requires a multidisciplinary approach, with close collaboration between hematologists/oncologists, geriatricians, nurses, pharmacists, and supportive care providers to optimize treatment outcomes and enhance the quality of life for patients affected by this challenging disease.